Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.35 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.33 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11251790 | 0.92 | PARP10 (0.33) | PARP10PARP11PIM1CSNK1A1CDK5 | |
| Romifidine SCHEMBL5898394 | 0.87 | PARP10 (0.31) | PARP10PARP11 | |
| SCHEMBL11468136 | 0.87 | MAPT (0.32) | PARP10PARP11 | |
| Romifidine SCHEMBL9623631 | 0.85 | PARP10 (0.30) | PARP10PARP11 | |
| Clonidine SCHEMBL1369066 | 0.75 | MAPT (0.34) | DYRK1ACLK4DYRK1B | |
| SCHEMBL10879541 | 0.75 | ALOX5 (0.34) | — | |
| SCHEMBL10880421 | 0.75 | GAA (0.39) | — | |
| SCHEMBL11099097 | 0.75 | ALDH1A1 (0.31) | — | |
| SCHEMBL10879937 | 0.75 | AXL (0.30) | — | |
| SCHEMBL5155034 | 0.75 | PARP10 (0.31) | PARP10PARP11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1981498-A2 | USE OF 2-IMIDAZOLES FOR THE TREATMENT OF CNS DISORDERS | F. Hoffmann-la Roche AG (CH) | 2008-10-22 | — | — | EP | claimed |
| US-20070197569-A1 | Method for treating central nervous system disorders with substituted 2-imidazoline derivatives | HOFFMANN-LA ROCHE INC. | 2007-08-23 | — | — | US | claimed |
| WO-2007090720-A2 | USE OF 2-IMIDAZOLES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-16 | — | — | WO | claimed |
| EP-1981498-A2 | USE OF 2-IMIDAZOLES FOR THE TREATMENT OF CNS DISORDERS | F. Hoffmann-la Roche AG (CH) | 2008-10-22 | — | — | EP | disclosed |
| US-20070197569-A1 | Method for treating central nervous system disorders with substituted 2-imidazoline derivatives | HOFFMANN-LA ROCHE INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070197569-A1 | Method for treating central nervous system disorders with substituted 2-imidazoline derivatives | HOFFMANN-LA ROCHE INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070197569-A1 | Method for treating central nervous system disorders with substituted 2-imidazoline derivatives | HOFFMANN-LA ROCHE INC. | 2007-08-23 | — | — | US | disclosed |
| WO-2007090720-A2 | USE OF 2-IMIDAZOLES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007090720-A2 | USE OF 2-IMIDAZOLES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-16 | — | — | WO | disclosed |
| EP-0083729-B1 | SUBSTITUTED 1-BENZOYL-2-PHENYLIMINO-IMIDAZOLIDINES, THEIR ACID ADDITION SALTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CHEMIE LINZ AKTIENGESELLSCHAFT (AT) | 1986-02-26 | — | — | EP | disclosed |
| EP-0083729-A1 | Substituted 1-benzoyl-2-phenylimino-imidazolidines, their acid addition salts, process for their preparation and pharmaceutical compositions containing them | CHEMIE LINZ AKTIENGESELLSCHAFT (AT) | 1983-07-20 | — | — | EP | disclosed |
| EP-0006451-B1 | IMIDAZO (1,2-A) IMIDAZOLES, THEIR ACID ADDITION SALTS, MEDICAMENTS CONTAINING THEM AND PROCESS FOR THEIR PREPARATION | C.H. BOEHRINGER SOHN (DE) | 1982-04-14 | — | — | EP | disclosed |
| US-4210659-A | BRADYCARDIACS | BOEHRINGER INGELHEIM GMBH (DE) | 1980-07-01 | — | — | US | disclosed |
| EP-0007991-A1 | Substituted 2-phenylamino-imidazolines-(2), their acid addition salts, medicaments containing them and processes for their preparation | C.H. BOEHRINGER SOHN (DE) | 1980-02-20 | — | — | EP | disclosed |
| EP-0007406-A1 | Substituted 2-phenylamino-imidazolines-(2), their acid addition salts, medicaments containing them and processes for their preparation | C.H. BOEHRINGER SOHN (DE) | 1980-02-06 | — | — | EP | disclosed |
| EP-0007428-A1 | Substituted 2-phenylamino-imidazolines-(2), their acid addition salts, medicaments containing them and processes for their preparation | C.H. BOEHRINGER SOHN (DE) | 1980-02-06 | — | — | EP | disclosed |
| EP-0006451-A1 | Imidazo (1,2-a) imidazoles, their acid addition salts, medicaments containing them and process for their preparation | C.H. BOEHRINGER SOHN (DE) | 1980-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197569-A1 | Method for treating central nervous system disorders with substituted 2-imidazoline derivatives | CRY1, HTR2C, PER2 | PARP10 3103/4885PARP11 2943/4885PIM1 4620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.